Sartorius AG

SRT

Company Profile

  • Business description

    Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.

  • Contact

    Otto-Brenner-Strasse 20
    GottingenNI37079
    DEU

    T: +49 5513080

    E: [email protected]

    https://www.sartorius.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2025

    Employees

    13,878

Stocks News & Analysis

stocks

Earnings from our top global lithium pick

Shares rise on improved free cash flow generation.
stocks

After slump this ASX share may be an opportunity

Lower than expected guidance led to a sell-off.
stocks

Investment decisions in overvalued bank drive strong results

Shares fall despite a broadly unchanged outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,109.4052.500.58%
CAC 408,055.51105.331.32%
DAX 4023,959.99390.031.65%
Dow JONES (US)47,353.85366.750.78%
FTSE 1009,787.15104.581.08%
HKSE26,649.06407.231.55%
NASDAQ23,524.25519.712.26%
Nikkei 22550,911.76635.391.26%
NZX 50 Index13,617.4818.270.13%
S&P 5006,829.74100.941.50%
S&P/ASX 2008,835.9044.100.50%
SSE Composite Index4,018.6021.040.53%

Market Movers